Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for the Treatment of Rett Syndrome
NCT06199700Phase 1Completed
- Sponsor
- Children's Hospital of Fudan University
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of esketamine in Rett syndrome (RTT), sponsored by Children's Hospital of Fudan University. Primary endpoints: Efficacy of treatment with Esketamine at 6 months, Incidence of Adverse events at 5 weeks and 1 more. Started Nov 2023; status: completed.
02
Drugs
esketamine
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on NCT06199700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06199700.